Bioventus (BVS) Gross Profit (2020 - 2026)

Bioventus (BVS) has reported Gross Profit for 7 consecutive years, with $105.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Gross Profit rose 3.5% year-over-year to $105.7 million; the trailing twelve-month figure through Jun 2026 stood at $399.4 million (up 4.74% YoY), and the FY2025 full-year result was $388.2 million, changed 0.02% from the prior year.
• Gross Profit rose to $105.7 million in Q2 2026 per BVS's latest filing, from $90.8 million in the prior quarter.
• Across five years, Gross Profit topped out at $108.8 million in Q4 2025 and bottomed at $73.9 million in Q2 2023.
• Historically, Gross Profit has averaged $90.7 million across 5 years, with a median of $89.9 million in 2023.
• The widest YoY moves for Gross Profit: up 27.11% in 2022, down 15.47% in 2022.
• Over 5 years, Gross Profit stood at $74.2 million in 2022, then advanced by 16.33% to $86.3 million in 2023, then advanced by 18.95% to $102.7 million in 2024, then grew by 5.97% to $108.8 million in 2025, then slipped by 2.86% to $105.7 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $105.7 million, $90.8 million, and $108.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.